for patients. Adaptations of this approach might also prove 
useful in the treatment of other human diseases. 
Specifically, we plan: 
1) To establish a safe and effective dose to introduce 
either a plasmid vector encoding recombinant HLA-B7 with 
p-2 microglobulin. Potentially, a plasmid vector 
encoding recombinant HLA-B7 and a cytokine gene could be 
incorporated in the future. 
2) To confirm expression of these genes introduced directly 
into tumor cells in vivo. 
3) To analyze the specificity of the immune response against 
this antigen in vivo by analyzing cellular and humoral 
immunity. 
Recombinant DNA Research, Volume 17 
[707] 
